Vanda Pharmaceuticals (VNDA) Net Cash Flow (QoQ) (2010 - 2026)
Vanda Pharmaceuticals (VNDA) Net Cash Flow (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,440.76 Bn | 66,440.47 Bn | - |
| 2 | Nanobiotix | 1,880.51 Bn | 1,880.45 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 467.94 Bn | 463.15 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.63 Bn | 115.38 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.30 Bn | 61.54 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.81 Bn | 62.81 Bn | - |
| 8 | Argenx Se | 55.78 Bn | 50.59 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn |
| 10 | Vanda Pharmaceuticals | 313.35 Mn | 111.04 Mn | 48.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -307.71% |
| Dec 31, 2025 | 237.36% |
| Sep 30, 2025 | 65.16% |
| Jun 30, 2025 | -428.14% |
| Mar 31, 2025 | 366.65% |
| Dec 31, 2024 | 180.07% |
| Sep 30, 2024 | 88.63% |
| Jun 30, 2024 | -108.38% |
| Mar 31, 2024 | 77.59% |
| Dec 31, 2023 | -242.79% |
| Sep 30, 2023 | 116.30% |
| Jun 30, 2023 | -193.16% |
| Mar 31, 2023 | 156.41% |
| Dec 31, 2022 | 1,056.23% |
| Sep 30, 2022 | -1.75% |
| Jun 30, 2022 | -158.89% |
| Mar 31, 2022 | 803.76% |
| Dec 31, 2021 | 124.19% |
| Sep 30, 2021 | 54.15% |
| Jun 30, 2021 | -233.85% |